- About
- Home
- Introduction
- Statistics
- Programs
- Dignet
- Gene
- GenePair
- BioSummarAI
- Help & Docs
- Documents
- Help
- FAQs
- Links
- Acknowledge
- Disclaimer
- Contact Us
Gene Information
Gene symbol: SPATA2
Gene name: spermatogenesis associated 2
HGNC ID: 14681
Synonyms: KIAA0757, PD1, tamo
Related Genes
| # | Gene Symbol | Number of hits |
| 1 | CD4 | 1 hits |
| 2 | CD8A | 1 hits |
| 3 | CTAG1B | 1 hits |
| 4 | CTLA4 | 1 hits |
| 5 | ERBB2 | 1 hits |
| 6 | GZMA | 1 hits |
| 7 | GZMB | 1 hits |
| 8 | IL4 | 1 hits |
| 9 | WT1 | 1 hits |
Related Sentences
| # | PMID | Sentence |
| 1 | 19091870 | Higher CS also correlated with higher levels of mRNAs for PD-1, CD4, CD8, F4/80, interleukin-4, gamma interferon, granzyme A, and granzyme B in both cornea and TG. |
| 2 | 19091870 | These results suggest that (i) the immunopathology induced by HSV-1 infection does not correlate with primary virus replication in the eye; (ii) increased CS appears to correlate with increased latency in the TG, although the possible cause-and-effect relationship is not known; and (iii) increased latency in mouse TG correlates with higher levels of PD-1 mRNA, suggesting exhaustion of CD8+ T cells. |
| 3 | 19091870 | Higher CS also correlated with higher levels of mRNAs for PD-1, CD4, CD8, F4/80, interleukin-4, gamma interferon, granzyme A, and granzyme B in both cornea and TG. |
| 4 | 19091870 | These results suggest that (i) the immunopathology induced by HSV-1 infection does not correlate with primary virus replication in the eye; (ii) increased CS appears to correlate with increased latency in the TG, although the possible cause-and-effect relationship is not known; and (iii) increased latency in mouse TG correlates with higher levels of PD-1 mRNA, suggesting exhaustion of CD8+ T cells. |
| 5 | 26377084 | These include vaccine approaches to elicit strong specific immune responses to tumor antigens such as WT-1, HER2 and NY-ESO-1, approaches involving adoptive transfer of in vitro-expanded, naturally arising or genetically engineered tumor-specific lymphocytes, therapeutic administration of monoclonal antibodies to target and eliminate tumor cells, and approaches that inhibit or destroy the molecular or cellular mediators of cancer-induced immunosuppression, such as CTLA-4, PD-1 or Treg cells. |